MedTrace Logo

Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes

NCT00145925 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 11140

Last updated 2025-04-11

No results posted yet for this study

Summary

The purpose of this study is to provide information on the risks and benefits of routine blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a result of cardiovascular disease), as well as new or worsening diabetic eye and kidney disease.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Perindopril-indapamide

DRUG

Gliclazide MR-based glucose lowering

Sponsors & Collaborators

  • Institut de Recherches Internationales Servier

    collaborator OTHER

  • University of Sydney

    collaborator OTHER

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • The George Institute

    lead OTHER

Principal Investigators

  • John Chalmers, MB BS PhD · The George Institute

  • Stephen W MacMahon, BSc PhD MPH · The George Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
55 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Australia
  • Canada
  • China
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00145925 on ClinicalTrials.gov